Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
micardis
Synonyms :
Class :
Angiotensin receptor blockers, Anti-hypertensive
Brand Name :
micardis
Synonyms :
Class :
Angiotensin receptor blockers, Anti-hypertensive
Dosage Forms & Strengths
Oral capsule/tablet:
20mg,40mg,80mg
Initially:
40 - 80
mg/day
Tablet
Orally
every 24 hours
2 - 4
weeks
80
mg
Tablet
Orally
every day
Dose Adjustments
Renal impairment: No dosage adjustment necessary
Hepatic impairment: Begin therapy with a low dose, gradually titrate, and continuously monitor
80
mg
Tablet
Orally
every day
Dose Adjustments
Renal impairment: No dosage adjustment necessary
Hepatic impairment: Begin therapy with a low dose, gradually titrate, and continuously monitor
Safety and efficacy not established
Refer to adult dosing
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
may decrease the effects of each other
may decrease the effects of each other
may Increase the adverse effect of NSAIDs
may Increase the adverse effect of NSAIDs
may Increase the adverse effect of NSAIDs
may Increase the adverse effect of NSAIDs
may Increase the adverse effect of NSAIDs
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may increase the adverse/toxic effect of angiotensin ii receptor blockers
may increase the adverse/toxic effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin II receptor blockers
may increase the adverse effect of angiotensin II receptor blockers
may increase the adverse effect of angiotensin II receptor blockers
may increase the adverse effect of angiotensin II receptor blockers
may increase the adverse effect of angiotensin II receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
aliskiren: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonists
lithium: they may enhance the serum concentration of Angiotensin II Receptor antagonist
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may enhance the serum concentration of angiotensin ii receptor blockers
may enhance the serum concentration of angiotensin ii receptor blockers
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
may increase the metabolism of each other
May enhances the effects of the other by pharmacodynamic synergism
may increase the toxicity of each other by pharmacodynamic synergism
It may enhance the toxicity effects when combined with moexipril by pharmacodynamic synergism
may increase the adverse effect of telmisartan
it increases the toxicity of angiotensin II receptor blockers
it may enhance the serum potassium levels
it may enhance the serum potassium levels
it may enhance the serum potassium levels
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
it may enhance the serum potassium levels
may decrease the serum potassium levels
it may enhance the serum potassium levels
it may enhance the serum potassium levels
it may enhance the serum potassium levels
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
it may enhance the serum potassium levels
it may enhance the serum potassium levels
it may enhance the serum potassium levels
it may enhance the serum potassium levels
May enhances the effects of the other by pharmacodynamic synergism
may enhance the serum concentration of telmisartan
may enhance the serum concentration of telmisartan
may enhance the serum concentration of telmisartan
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
spironolactone and hydrochlorothiazide
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increasingly adverse effect when combined with NSAIDs
it increases the effect of hyperkalemia of angiotensin II receptor blockers
may enhance the effects of the other by pharmacodynamic synergism
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the orthostatic hypotensive effect of dapoxetine
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
polyethylene glycol and electrolytes
It may increase the nephrotoxic effect when combined with polyethylene Glycol-electrolyte Solution
nicorandil: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
they decrease the effect of hypertension of angiotensin II
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin II Receptor antagonist
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
may increase the toxicity of each other when combined
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
Frequency defined:
1-10%
Upper respiratory tract infection (7%)
Back pain (3%)
Sinusitis (3%)
Diarrhea (3%)
Cough (1.6%)
Pharyngitis (1%)
Frequently undefined:
Angina pectoris
Tachycardia
Arthritis
Anxiety
Eczema
Cystitis
Depression
Gastritis
Otitis media
Pruritus
Urticaria
Vomiting
xerostomia
Be cautious in patients with hypersensitivity to telmisartan and co-administration of aliskiren in diabetic patients
Pregnancy consideration:
Not recommended to use in pregnancy
Pregnancy category: D
Lactation: The excretion of the drug in human breast milk is unknown
Pregnancy category:
Patient information leaflet
Generic Name: telmisartan
Pronounced: [ TEL-mi-SAR-tan ]
Why do we use telmisartan?
Telmisartan is an angiotensin II receptor block used to treat hypertension.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
